Tirzepatide 7.5 mg SC to be assessed for increasing esophageal acid exposure time in adults with obesity

Obesity is associated with various gastrointestinal issues, including gastroesophageal reflux disease (GERD). Current treatments for GERD often focus on acid suppression or surgical intervention. Tirzepatide, a dual GLP-1 and GIP receptor agonist, is highly effective for weight loss and type 2 diabetes. Its mechanism involves slowing gastric emptying, which could theoretically impact esophagogastric junction function and reflux burden. This study aims to understand these potential effects.

Written by TitrateLab, separately from the study summarized above.